Poseida Therapeutics, Inc. Retained Earnings
Poseida Therapeutics, Inc. had Retained Earnings of -$629.70 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2024-11-07
- 2024-09-30: Retained Earnings (Accumulated Deficit) -$629.70M.
- 2024-06-30: Retained Earnings (Accumulated Deficit) -$649.94M.
- 2024-03-31: Retained Earnings (Accumulated Deficit) -$618.57M.
- 2023-12-31: Retained Earnings (Accumulated Deficit) -$594.29M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2024-09-30 | -$629.70M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$649.94M 10-Q · filed 2024-08-05 |
| 2024-03-31 | -$618.57M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$594.29M 10-Q · filed 2024-11-07 |
| 2023-09-30 | -$568.94M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$537.16M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$509.71M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$470.86M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$437.54M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$507.95M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$464.92M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$406.86M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$408.33M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$365.90M 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$320.20M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$281.88M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$245.74M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$211.32M 10-Q · filed 2020-08-20 |
| 2019-12-31 | -$152.22M 10-K · filed 2021-03-11 |